; or (ii) is exempt from the provisions of section 505 of such Act relating to new drugs because— (I) it is intended solely for investigational use as described in section 505(i) of such Act; and (II) such product is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application. . (b) Penalties Section 402 of the Controlled Substances Act ( 21 U.S.C. 842 ) is amended— (1) in subsection (a)(16), by inserting or subsection (f) after subsection (e) ; and (2) in subsection (c)(1)(D), by inserting or a schedule A substance after anabolic steroid . 6. Registration requirements for handlers of schedule A substances (a) Controlled Substances Act Section 303 of the Controlled Substances Act ( 21 U.S.C. 823 ) is amended— (1) in subsection (f), in the undesignated matter following paragraph (5)— (A) by inserting or A after schedule I each place it appears; and (B) by adding at the end the following: A separate registration for engaging in research with a controlled substance in schedule A for practitioners already registered under this part to engage in research with controlled substances in schedule I shall not be required. The Secretary shall determine the merits of the research protocol submitted by the practitioner registering to engage in research with a controlled substance in schedule A, and the Attorney General may deny or revoke the registration only on a ground specified in section 304. ; and (2) by adding at the end the following: (k) (1) The Attorney General shall register an applicant to manufacture schedule A substances if— (A) the applicant demonstrates that the schedule A substances will be used for research, analytical, or industrial purposes approved by the Attorney General